Author name: Immunwork Web Team

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

Reported /

Congratulations to our founder, Dr. Tse-Wen Chang, the inventor of Xolair.We are thrilled to learn that Xolair’s potential benefits are extending to more patients, especially those with food allergies. The website link: https://www.businesswire.com/news/home/20240215550080/en/FDA-Approves-Xolair-as-First-and-Only-Medicine-for-Children-and-Adults-With-One-or-More-Food-Allergies

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies Read More »

Immunwork 2024 Investor Meeting – Results Presentation

News /

The founder of Immunwork and T-E Meds, Dr. Tse-Wen Chang, shared the latest developments of the two companies on 11th January. He further announced Immunwork’s planned entry into the clinical stage in 2024. The two long-acting drugs, TE-8105 and TE-8214, are designed to target type-II diabetes, obesity, fatty liver diseases, and neuroendocrine tumors (NETs) as

Immunwork 2024 Investor Meeting – Results Presentation Read More »

Join our presentation at the World ADC San Diego 2023

Meeting /

Dr. Hsing-Mao Chu, CEO at T-E Meds, will be presenting at the prestigious World ADC conference in San Diego on October 16th (Monday) from 4:30 PM to 5:00 PM. He will unveil our groundbreaking joint technology of “Drug Bundles” and “Glycan Modification” in the applications of ADCs. He will also show how this innovative approach enables precise site-specific

Join our presentation at the World ADC San Diego 2023 Read More »

【Reported by Taiwan Global Bio Monthly】The president – Dr. Tse-Wen Chang presents the Immunwork’s latest progress in the 40th anniversary activities of Development Center for Biotechnology (DCB)

Reported /

Website link: https://news.gbimonthly.com/tw/article/show.php?num=60662&utm_source=dable

【Reported by Taiwan Global Bio Monthly】The president – Dr. Tse-Wen Chang presents the Immunwork’s latest progress in the 40th anniversary activities of Development Center for Biotechnology (DCB) Read More »

Immunwork’s latest research result is published in J. Med. Chem.

Scientific Publication /

Exciting News! Immunwork’s Latest Published Paper Offers Promising Solutions for Pancreatic Cancer Treatment, Diagnostics, and Applications in ADC and ARC! We are thrilled to announce the publication of our paper, “Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy,” in the prestigious Journal of Medicinal Chemistry. Led by Dr.

Immunwork’s latest research result is published in J. Med. Chem. Read More »

Scroll to Top